Anti-SMYD1 Polyclonal Antibody for WB, IHC-P, IF/ICC, ELISA - Q8NB12

Core Product Specifications and Parameters

Biological Background: SMYD1 Function and Localization

• SMYD1 (SET and MYND domain-containing protein 1), also known as BOP, KMT3D, ZMYND18, or ZMYND22, is a histone-lysine N-methyltransferase.
• It catalyzes mono-, di-, and trimethylation of histone H3 at lysine 4 (H3K4me1/2/3), an epigenetic mark often associated with active transcription, yet SMYD1 acts as a transcriptional repressor.
• SMYD1 is essential for cardiomyocyte differentiation and cardiac morphogenesis, underscoring its critical role in heart development.
• The protein contains a SET domain responsible for methyltransferase activity and a MYND zinc finger domain likely involved in protein-protein interactions, along with additional zinc finger motifs (keywords: Zinc, Zinc-finger, Metal-binding).
• It localizes to both the cytoplasm and nucleus, suggesting dynamic shuttling or compartment-specific functions.
• Expression is predominantly restricted to heart and skeletal muscle, consistent with its developmental role in these tissues.
• SMYD1 binds DNA (DNA-binding keyword) and may directly regulate muscle-specific gene expression programs.
• It is an S-adenosyl-L-methionine-dependent methyltransferase and is part of the reference proteome with experimental proteomics identification.

Experimental Guidance and Technical Tips

• For Western blotting, the predicted molecular weight is ~57 kDa; however, post-translational modifications or isoform differences may cause slight mobility shifts. Validate with appropriate positive controls (e.g., cardiac or skeletal muscle lysates).
• When performing immunohistochemistry (IHC-P), consider heat-induced antigen retrieval methods and titrate the antibody to optimize signal-to-noise ratio. Test on known positive tissues such as heart or skeletal muscle sections.
• For immunofluorescence (IF/ICC), fixation and permeabilization conditions may need optimization, and include isotype controls to assess specificity.
• As a polyclonal antibody, lot-to-lot consistency can vary; consider screening new lots against knock-out or knock-down samples to confirm target specificity.
• The immunogen covers amino acids 1-350, which is the N-terminal region; ensure that detected bands correspond to the expected size and that alternative isoforms (if any) are considered.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio offers diagnostic manufacturers, laboratories, and research institutes a streamlined source for IVD raw materials, technical support, and consulting—guiding projects from concept to clinical application. For epigenetic and cardiac research, we provide this SMYD1 polyclonal antibody alongside validated antibody pairs, optimized monoclonal/polyclonal antibodies, bulk ancillary reagents, and sourcing of rare target raw materials. Whether advancing cardiomyocyte differentiation studies or developing new diagnostic assays, our integrated platform simplifies procurement and accelerates your workflow.